Colorectal cancer screening: Comparison of transferrin and immuno fecal occult blood test

World Journal of Gastroenterology

Volumn 18, Issue 21, 2012, Pages 2682-2688

  Chen, Ji Gui ^a   Cai, Juan ^b   Wu, Huan Lei ^b   Xu, Hua ^b   Zhang, Yu Xing ^a   Chen, Chao ^a   Wang, Qian ^a   Xu, Jun ^a   Yuan, Xiang Lin ^b  

^a The Eighth Hospital   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Colorectal cancer; Immuno fecal occult blood test; Precancerous lesions; Transferrin; Transferrin dipstick test

Indexed keywords

TRANSFERRIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; COLON BIOPSY; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FECES; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNE FUNCTION TEST; IMMUNO FECAL OCCULT BLOOD TEST; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PRECANCER; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TRANSFERRIN BLOOD LEVEL; TRANSFERRIN DIPSTICK TEST;

EID: 84863089061     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i21.2682     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249
2. Wei YS, Lu JC, Wang L, Lan P, Zhao HJ, Pan ZZ, Huang J, Wang JP. Risk factors for sporadic colorectal cancer in southern Chinese. World J Gastroenterol 2009; 15: 2526-2530
3. Lei T, Mao WM, Yang HJ, Chen XZ, Lei TH, Wang X, Ying Q, Chen WQ, Zhang SW. [Study on cancer incidence through the Cancer Registry Program in 11 Cities and Counties, China.]. Zhonghua Liuxingbingxue Zazhi 2009; 30: 1165-1170
4. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-1549
5. Logan RF. Review: faecal occult blood test screening reduces risk of colorectal cancer mortality. Evid Based Med 2009; 14: 15
6. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010; 60: 99-119
7. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-1607
8. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, Pessi MA, Prochilo T, Quadri A, Gatta G, de Braud F, Wils J. Colon cancer. Crit Rev Oncol Hematol 2010; 74: 106-133
9. Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin 2003; 53: 44-55
10. Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005; 142: 81-85
11. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 1462-1470
12. Oort FA, Terhaar Sive Droste JS, Van Der Hulst RW, Van Heukelem HA, Loffeld RJ, Wesdorp IC, Van Wanrooij RL, De Baaij L, Mutsaers ER, van der Reijt S, Coupe VM, Berkhof J, Bouman AA, Meijer GA, Mulder CJ. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test. Aliment Pharmacol Ther 2010; 31: 432-439
13. Parra-Blanco A, Gimeno-García AZ, Quintero E, Nicolás D, Moreno SG, Jiménez A, Hernández-Guerra M, Carrillo-Palau M, Eishi Y, López-Bastida J. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 2010; 45: 703-712
14. Young GP, Cole S. New stool screening tests for colorectal cancer. Digestion 2007; 76: 26-33
15. Kronborg O, Regula J. Population screening for colorectal cancer: advantages and drawbacks. Dig Dis 2007; 25: 270-273
16. Uchida K, Matsuse R, Miyachi N, Okuda S, Tomita S, Miyoshi H, Hirata I, Tsumoto S, Ohshiba S. Immunochemical detection of human blood in feces. Clin Chim Acta 1990; 189: 267-274
17. Burton RM, Landreth KS, Barrows GH, Jarrett DD, Songster CL. Appearance, properties, and origin of altered human hemoglobin in feces. Lab Invest 1976; 35: 111-115
18. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-627
19. Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, Ross ME. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3: 47-53
20. Woolf SH. A smarter strategy? Reflections on fecal DNA screening for colorectal cancer. N Engl J Med 2004; 351: 2755-2758
21. Hakama M, Coleman MP, Alexe DM, Auvinen A. Cancer screening: evidence and practice in Europe 2008. Eur J Cancer 2008; 44: 1404-1413
22. Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 2004; 53: 1329-1333
23. McDonald S, Lyall P, Israel L, Coates R, Frizelle F. Why barium enemas fail to identify colorectal cancers. ANZ J Surg 2001; 71: 631-633
24. Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol 2009; 7: 770-775; quiz 711
25. Rabeneck L, Paszat LF, Hilsden RJ, Saskin R, Leddin D, Grunfeld E, Wai E, Goldwasser M, Sutradhar R, Stukel TA. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008; 135: 1899-1906, 1906.e1
26. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin 2008; 58: 161-179
27. Pox CP, Schmiegel W. Role of CT colonography in colorectal cancer screening: risks and benefits. Gut 2010; 59: 692-700
28. Chiang CH, Jeng JE, Wang WM, Jheng BH, Hsu WT, Chen BH. A comparative study of three fecal occult blood tests in upper gastrointestinal bleeding. Kaohsiung J Med Sci 2006; 22: 223-228
29. Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996; 91: 927-934
30. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006; 94: 1898-1905
31. Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 2005; 5: 4625-4636
32. Saitoh O, Kojima K, Kayazawa M, Sugi K, Tanaka S, Nakagawa K, Teranishi T, Matsuse R, Uchida K, Morikawa H, Hirata I, Katsu K. Comparison of tests for fecal lactoferrin and fecal occult blood for colorectal diseases: a prospective pilot study. Intern Med 2000; 39: 778-782
33. Hirata I, Hoshimoto M, Saito O, Kayazawa M, Nishikawa T, Murano M, Toshina K, Wang FY, Matsuse R. Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases. World J Gastroenterol 2007; 13: 1569-1574
34. Sheng JQ, Li SR, Wu ZT, Xia CH, Wu X, Chen J, Rao J. Transferrin dipstick as a potential novel test for colon cancer screening: a comparative study with immuno fecal occult blood test. Cancer Epidemiol Biomarkers Prev 2009; 18: 2182-2185
35. Lönnerdal B, Iyer S. Lactoferrin: molecular structure and biological function. Annu Rev Nutr 1995; 15: 93-110
36. Chew MH, Suzanah N, Ho KS, Lim JF, Ooi BS, Tang CL, Eu KW. Colorectal cancer mass screening event utilising quantitative faecal occult blood test. Singapore Med J 2009; 50: 348-353
37. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434-437